Teva Pharmaceutical Industries Ltd (NYSE:TEVA) shares shot up 6.1% during trading on Monday . The company traded as high as $7.44 and last traded at $7.44, 18,343,414 shares traded hands during trading. An increase of 16% from the average session volume of 15,806,336 shares. The stock had previously closed at $7.01.

TEVA has been the subject of a number of recent research reports. Argus upgraded Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and set a $12.00 price objective for the company in a research report on Friday, July 5th. Wolfe Research began coverage on shares of Teva Pharmaceutical Industries in a report on Friday, July 19th. They issued a “peer perform” rating and a $9.00 target price on the stock. Bank of America cut shares of Teva Pharmaceutical Industries from a “buy” rating to an “underperform” rating and decreased their price target for the stock from $19.00 to $9.00 in a research note on Thursday, May 30th. Oppenheimer set a $12.00 price target on shares of Teva Pharmaceutical Industries and gave the stock a “buy” rating in a report on Wednesday, June 12th. Finally, Cowen set a $9.00 price objective on shares of Teva Pharmaceutical Industries and gave the company a “hold” rating in a research report on Wednesday, August 7th. Six investment analysts have rated the stock with a sell rating, fifteen have issued a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of $12.80.

The company has a debt-to-equity ratio of 1.73, a current ratio of 0.96 and a quick ratio of 0.62. The firm’s 50-day moving average is $7.21 and its 200 day moving average is $11.25. The stock has a market cap of $8.83 billion, a price-to-earnings ratio of 2.97, a price-to-earnings-growth ratio of 0.78 and a beta of 1.68.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings results on Wednesday, August 7th. The company reported $0.57 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.55 by $0.02. Teva Pharmaceutical Industries had a negative net margin of 21.94% and a positive return on equity of 16.04%. The company had revenue of $4.34 billion for the quarter, compared to the consensus estimate of $4.25 billion. During the same quarter last year, the firm posted $0.78 earnings per share. Teva Pharmaceutical Industries’s revenue was down 7.7% on a year-over-year basis. On average, sell-side analysts forecast that Teva Pharmaceutical Industries Ltd will post 2.25 EPS for the current year.

Institutional investors and hedge funds have recently modified their holdings of the stock. First Interstate Bank purchased a new stake in Teva Pharmaceutical Industries during the second quarter valued at about $28,000. Pacer Advisors Inc. acquired a new position in shares of Teva Pharmaceutical Industries in the 2nd quarter valued at about $32,000. Kavar Capital Partners LLC acquired a new position in shares of Teva Pharmaceutical Industries in the 2nd quarter valued at about $35,000. G&S Capital LLC grew its holdings in shares of Teva Pharmaceutical Industries by 99.4% during the 2nd quarter. G&S Capital LLC now owns 4,012 shares of the company’s stock worth $37,000 after purchasing an additional 2,000 shares during the period. Finally, NEXT Financial Group Inc grew its holdings in shares of Teva Pharmaceutical Industries by 384.8% during the 2nd quarter. NEXT Financial Group Inc now owns 4,276 shares of the company’s stock worth $39,000 after purchasing an additional 3,394 shares during the period. 57.85% of the stock is currently owned by institutional investors and hedge funds.

Teva Pharmaceutical Industries Company Profile (NYSE:TEVA)

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.

Read More: Candlestick

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.